

Qalsody® (tofersen) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of treat						·	
	last treatment / / Phone:		Fax:				
Precertification Requested By: _			Phon	e	гах		
A. PATIENT INFORMATION		Loot Name:			DOB:		
First Name:		Last Name:	0:4		DOB:	710	
Address:			City:		State:	ZIP:	
Home Phone:	Work Phone:		Cell Phone:	T	Email:	_	
Patient Current Weight: lbs o	rkgs Patient	t Height: inches	orcms	Allergies:			
B. INSURANCE INFORMATION							
Aetna Member ID #:	Does patient have other coverage? ☐ Yes ☐ No If yes, provide ID#: Carrier Name:						
Group #: Insured:		If yes, provide ID#: Insured:		Carrier Name:			
Medicare: ☐ Yes ☐ No If yes, p	rovide ID #:	Me	edicaid: LYes	s ☐ No If yes, pro\	ride ID #:		
C. PRESCRIBER INFORMATION		Loot Name		(Chaok On	a),] D.O. 🗌 N.P. 🗌 P.A.	
First Name:		Last Name:	Cit	(Crieck Ori	<u> </u>		
Address:		la "	City:	155. "	State:	ZIP:	
Phone: Fax:		St Lic #:	NPI #:	DEA #:	I	UPIN:	
Provider Email:		Office Contact Name			Phone:		
Specialty (Check one): Neurolo	_	-	Other:				
D. DISPENSING PROVIDER/ADM	NISTRATION INFOR	RMATION					
Place of Administration:	0.55		-	Provider/Pharmad	=		
☐ Self-administered ☐ Ph		-		Retail Phar	macy		
Outpatient Infusion Center			_ Specialt	y Pharmacy	☐ Other		
Center Name: Home Infusion Center							
Agency Name:			Address:				
Administration code(s) (CPT):			Phone:		Fax:		
Address:	-		TIN:		PIN:		
E. PRODUCT INFORMATION							
Request is for: Qalsody (tofersen)	Dose:		Frequ	ency:			
F. DIAGNOSIS INFORMATION - P	•						
Primary ICD Code:	iodoo irraiodio priirrai	Secondary ICD Co		Othor	ICD Code:		
G. CLINICAL INFORMATION - Red							
For ALL Requests (clinical document	•	ation must be complete	ra in no <u>orianoty</u> i	or an processmeation	roquosto.		
☐ Yes ☐ No Has the patient been	diagnosed with amyot	rophic lateral sclerosis (ALS)?				
	phic lateral sclerosis (A	ALS)?				n specializing in the	
Yes No Will the administration			a designated ger	ne therapy treatment of	enter?		
Please indicate the Initial Requests (clinical documents		ipy treatment center:					
·		ble to ALS (e.g. medica	l history and/or di	iagnostic testing inclu	ding nerve cond	fuction studies	
☐ Yes ☐ No Does the patient have a weakness attributable to ALS (e.g., medical history and/or diagnostic testing including nerve conduction studies, imaging, and laboratory values to support the diagnosis)?							
 Yes □ No Does the patient have an SOD1 mutation confirmed via genetic testing? Yes □ No Does the patient have a forced vital capacity (FVC) or slow vital capacity (SVC) greater than or equal to 45% of the predicted value for gender, 							
☐ Yes ☐ No Does the patient have height, and age?	a forced vital capacity	y (FVC) or slow vital cap	pacity (SVC) grea	ter than or equal to 4	o% of the predic	ted value for gender,	
☐ Yes ☐ No Does the patient have	a tracheostomy?						
Continuation Requests (clinical doc		=					
☐ Yes ☐ No Does the patient requ		-	e reguested modi	cation?			
	nonatou a onnicai peri	one nom ulciaby will lil		oution:			

Continued on next page



Qalsody® (tofersen) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB							
H. ACKNOWLEDGEMENT										
Request Completed By (Signature Required):			Date:	1	1					
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.										

The plan may request additional information or clarification, if needed, to evaluate requests.